Breast Cancer

ASCO® Meeting Library

Access official Highlights of the Day and Education Session videos and slides.

Plenary Session

A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial

Presenter: Wendy Y. Chen

Session Title: ASCO Plenary Series: February 2022 Session

Meeting: ASCO Plenary Series

Education Session

Clinical Implications of HER-2/Neu in GI Cancers and Beyond

Speaker: Daniel V.T. Catenacci, MD

Session Title: ASCO/American Association for Cancer Research (AACR) Joint Session: HER-2/Neu Alterations–Using Biology to Drive Therapeutic Options in Cancers of the Breast, Gut, and Beyond

Meeting: 2021 ASCO Annual Meeting

Education Session

Balancing Adherence and Quality of Life While Taking Endocrine Therapy

Speaker: Ines Maria Vaz Duarte Luis, PhD, MD

Session Title: The Controversies of Adjuvant Therapies for Premenopausal Women Diagnosed With Luminal Breast Cancers

Meeting: 2021 ASCO Annual Meeting

ASCO® Educational Book

Read peer-reviewed articles authored by the 2021 Annual Meeting Education Program faculty.

Harnessing Nutrition and Physical Activity for Breast Cancer Prevention and Control to Reduce Racial/Ethnic Cancer Health Disparities

The authors review the current evidence for racial/ethnic disparities in obesity and breast cancer risk and survival, discuss the evolution of nutrition/physical activity guidelines for cancer prevention and control, and provide an overview of lifestyle interventions, including barriers and facilitators in implementation and dissemination science among minority populations underrepresented in research.

Disparities in Breast Cancer Associated With African American Identity

Persistent disparities in the burden of breast cancer between African Americans and White Americans have been documented over many decades.

ASCO® Guidelines

View recently published clinical practice guidelines from ASCO.

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer

To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer.

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer.

Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer

To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Health (Cancer Care Ontario [CCO]) adjuvant bone-modifying agents in breast cancer guideline.

ASCO® Education

Take a selection of ASCO Education eLearning courses.

Treatment of an Older Patient with Early-Stage, HER2-Positive Breast Cancer

This case-based course details the multi-step process of treatment decision-making for an older woman with early-stage, HER2-positive and hormone receptor-positive breast cancer.

First-line Treatment: HR-Positive and HER2-Positive Metastatic Breast Cancer

This case-based course discusses implementation of recent clinical research findings regarding therapy for hormone receptor-positive, HER2-positive, metastatic breast cancer into clinical practice.

Screening and Prevention of Breast Cancer

This course discusses modifiable risk factors for breast cancer and approaches to breast cancer risk assessment, including risk assessment tools and models. Breast cancer screening recommendations are described, along with key screening and diagnostic tools.

ASCO Daily News®

Stay updated with news from ASCO’s official conference reporter.

ASCO Refines Guidance on Using Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

April 27, 2022

Prosigna and the Breast Cancer Index may be used in postmenopausal patients with breast cancer that is node-negative, ER-positive, and HER2-negative.

ASCO Guideline Rapid Update Addresses the Use of Neoadjuvant Pembrolizumab in High-Risk Early-Stage TNBC

April 20, 2022

The guideline update recommends pembrolizumab in combination with neoadjuvant chemotherapy, followed by adjuvant pembrolizumab after surgery, for patients with T1cN1-2 to T2-4N0 early-stage TNBC.

Remote Behavioral Weight Loss Intervention Is Effective for Breast Cancer Survivors

April 13, 2022

Approximately one-half of breast cancer survivors receiving a behavioral weight loss intervention, with or without the addition of pharmacotherapy, achieved at least 5% weight loss at 8 weeks.

This site is intended for healthcare professionals in Europe and Japan only.

The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.

This program is supported by an educational grant from Daiichi Sankyo and brought to you by Springer Healthcare | Contact Us | Privacy Policy

Focus on Breast and Lung Cancer

Welcome to the ASCO Direct™ – Focus on Breast and Lung Cancer educational portal, with complimentary access to official ASCO Meetings, Publications and Education content. Provided for healthcare professionals resident in Europe and Japan only.

Review the terms and conditions below to access this website.

Disclaimer | Privacy Policy

This program is supported by an educational grant from Daiichi Sankyo and brought to you by Springer Healthcare.

Be the first to know!

By completing the form below you will receive new content alerts direct to your inbox.

* Required field
Email Address*
Enter Email Confirm Email
Area/Country of Residence*
Area of Interest*
Marketing Permissions*
- Yes, I agree to be contacted about future updates to this program.
Springer Healthcare Education
- Yes, I would like to hear about Springer Healthcare Education programs in the field of oncology.
CAPTCHA
Name
This field is for validation purposes and should be left unchanged.

Before you go....

We'd love your feedback!

Your feedback will help guide us in the next phase of this program. Please take a few minutes (estimated 2 minutes) to answer the following 6 questions.

No thanks, not at this time